Beyond Reporting - Safety surveillance analytics for medical devices...
Why Sustainable Biomanufacturing Must Start Earlier in The Process
The Emergence of 3D Printing in Expanding Clinical Research and Pharmaceutical Compounding
LYMPHOMA TREATMENT AT A CROSSROADS
Complex Journey from Innovation to Patient impact
EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
ExpreS2ion Biotechnologies
Vice President - Business Development
ExpreSion Biotechnologies protein expression system ExpreS is an important protein expression tool in the scientists tool box for protein expression The ExpreS platform has demonstrated in many instances its usefulness in RD with several ExpreSmade proteins having now been crystallized
Articles
Are We Ready to Ship Billions of COVID Vaccines Worldwide?
Theres no denying it has been a year of immense difficulty and disruptionMany now look forward to and the muchanticipated prospect of COVID vaccines as the gateway to global recovery Naturally as one of the the worlds leading logistics companies FedEx has an important role to play in vaccine shipment
Research Insights
Challenges And Strategies In Anti-cancer Nanomedicine Development: An Industry Perspective
Abstract Successfully translating anticancer nanomedicines from preclinical proof of concept to demonstration of therapeutic value in the clinic is challenging Having made significant advances with drug delivery technologies we must learn from other areas of oncology drug development where patient stratification and targetdriven design have improved patie
Case Studies
Cyclodextrins as Active Pharmaceutical Ingredients for The Treatment Of GM1-Gangliosidosis: A Feasibility Case Study
Abstract GMgangliosidosis is a rare lysosomal storage disorder characterized clinically by a wide range of variable neurovisceral ophthalmological and dysmorphic features Without enough functional galactosidase GMgangliosides cannot be degraded in lysosomes and accumulate to toxic levels in many tissues and organs particularly in the brain In s
Techno Trends
Daiichi Sankyo’s FLT3 Inhibitor Quizartinib Treats Relapsed/Refractory FLT3-ITD AML
Daiichi Sankyo Company Limited announced quizartinib an investigational FLT inhibitor for the treatment of adult patients with relapsedrefractory FLTITD Acute Myeloid Leukemia AML Quizartinib is the first FLT inhibitor to enhance overall survival as an oral single agent compared to chemotherapy in patients with relapsedrefractory AML with FLTITD an underlying drive...
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
From Gene Editing to Network Medicine
Prof. Dr. Hemanth Kumar Manikyam is a researcher in natural products chemistry and systems pharmacology. He is widely known as the father of Intrinsic Network Pharmacology (INP), an integrative framework combining artificial intelligence, biological network analysis, and traditional medicinal knowledge to explore complex therapeutic mechanisms and next-generation precision medicine.
Evolution of eCTD from version 1 to 4
Gouspasha is a seasoned professional with 12 years of experience in the pharmaceutical industry, specializing in eCTD (Electronic Common Technical Document) publishing and submission. With a strong focus on regulatory compliance and efficient document management, Gouspasha ensures seamless and timely submissions. Dedicated to maintaining the highest standards of quality and accuracy, Gouspasha remains committed to staying current with evo0lving industry trends and regulatory requirements.
Revolutionising Tuberculosis Treatment test
Ashok Aspatwar, MS, PhD, is an Adjunct Professor at Tampere University, Finland. His research focuses on carbonic anhydrases in Mycobacterium tuberculosis persistence and anti-TB drug development, using molecular biology, medicinal chemistry, and AI-driven bioinformatics to explore novel therapeutic pathways and target mechanisms in TB.
Rarchita Sharma, M. Pharm, is a researcher at SVKM's Institute of Pharmacy, specialising in novel drug delivery for CNS disorders. She has published seven papers on topics like regulatory filings, AI in stroke care, and cardiovascular drugs, aiming to advance therapeutic innovations in pharmaceutical sciences.
A BITTER PILL: Exploring the Realm of Drug Counterfeiting
Stephen Ward is Pinkerton’s the Vice President of East Coast USA. Established in 1850, Pinkerton National Detective Agency offers organizations in today’s modern age, a range of corporate risk management services from security consulting and investigations to executive protection, employment screening and protective intelligence.
Angelo Krizmanic is Pinkerton’s Vice President of Asia Pacific. Established in 1850, Pinkerton National Detective Agency offers organizations in today’s modern age, a range of corporate risk management services from security consulting and investigations to executive protection, employment screening and protective intelligence.
Endocrine Disrupting Compounds (EDCs)
Sintu Kumar Samanta has been working as an Assistant professor in IIIT Allahabad, India. He did Ph.D. and post-doctoral research from IIT Kharagpur and IISc Bangalore, India respectively. He is working in the area of Biochemistry and Nanobiotechnology. He published research work in several international journals and filed one Indian patent.
Pavan Kumar Gautamis presently working as a Post-Doctoral Fellow in the Department of Applied Sciences at IIIT Allahabad, India. He obtained Ph.D. from the University of Allahabad, India. His area of research is synthesis of nanoparticles for water remediation. He published his research work in many international journals.
press releasesRead more...
Waters Launches AI Link, Advancing AI-Enabled LC-MS Workflows from Research to Release
Waters Corporation announced that it has launched Waters AI Link a software capability that brings Anthropics Model Context Protocol MCP to its informatics platform and has joined Anthropics Model Hardware Standard MHS research program
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1
Takeda announced that ORZEYFUL oveporexton is now available in Japan and China for the treatment of narcolepsy type NT providing first access to clinicians to prescribe treatment with the new class of medicine ORZEYFUL is a firstinclass orexin receptor OXR agonist in tablet form designed to treat...
Merck Inaugurates State-of-the-Art ADVANCE Bioanalytical Facility on West Point, Pennsylvania, Campus
Merck known as MSD outside of the United States and Canada today inaugurated its stateoftheart ADVANCE research facility on its West Point Pennsylvania campus signaling a new chapter in global scientific discovery Pennsylvania Gov Josh Shapiro joined Merck executive leadership federal and state gove...
Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg
Alvotech a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited a global pharmaceutical company with a strategic focus on specialty hospital and rare disease medicines today announced the submissi...
Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals Inc a global commercialstage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases today announced the commercial launch of IMCIVREE setmelanotide in Japan to treat patients living with acquired hypothalamic obesity HO...
Scinai Expands CDMO Business with $5.1 Million Development and Clinical Manufacturing Agreement
Scinai Immunotherapeutics Ltd a biopharmaceutical company operating a growing contract development and manufacturing organization CDMO alongside an immunologyfocused therapeutic development platform today announced that its wholly owned subsidiary Scinai Biopharma Services Ltd has entered into a def...
EventsRead more...
21 - 23
Oct 2026Drug Formulation & Drug Delivery 2026
Paris, France
21 - 22
Oct 2026Advance Clinical Trials and Research 2026
Paris, France
22 - 23
Oct 2026PDA Aseptic Symposium 2026
Congress Square Nakanoshima, O...
26 - 28
Oct 2026ACHEMA Middle East 2026
RICEC, Riyadh, KSA, Saudi Arab...
26 - 28
Oct 2026World Orphan Drug Congress
RAI, Amsterdam, Netherlands
27 - 28
Oct 2026PM& AC 2026
Novotel Hyderabad Convention C...
28 - 30
Oct 2026BIOPLUS-INTERPHEX KOREA 2026
COEX, Seoul
02 - 04
Nov 2026Pharma Forum EMEA 2026
Dom Pedro Lisboa Hotel, Lisbon...
LATEST NEWSRead more...
Nxera Pharma Partners with Synmosa to Commercialise QUVIVIQ
Nxera Pharma has entered into an exclusive licensing supply and commercialisation agreement with Synmosa Biopharma to expand access to QUVIVIQ daridorexant a medicine used to treat insomnia across eight AsiaPacific markets QUVIVIQ was discovered and developed by Idorsia Pharmaceuticals
Vir Biotechnology Enters into Collaboration with Gilead Sciences to Develop T-cell Engagers for Solid Tumours
Vir Biotechnology has entered into a collaboration and licensing agreement with Gilead Sciences to discover and develop three novel Tcell engager TCE candidates for the treatment of solid tumours Tcell engagers are designed to direct T cells a type of immune cell towards cancer cells and help destro...
Zealand Pharma Enters into Collaboration with Generate Biomedicines on AI-Designed Protein Therapies for Metabolic Diseases
Zealand Pharma and Generate Biomedicines have entered into a multitarget collaboration and licensing agreement to develop proteinbased treatments for obesity and other metabolic diseases using artificial intelligence AI The collaboration will combine Zealand Pharmas expertise in metabolic diseases w...
Enodia Therapeutics Enters into Collaboration with Pfizer to Develop Small-Molecule Sec61 Inhibitors
Enodia Therapeutics has entered into a research collaboration and licensing agreement with Pfizer to discover and develop smallmolecule inhibitors targeting Sec a protein complex involved in the movement of newly formed proteins across cell membranes
InnoCare Announces Approval of Clinical Trial of Bispecific Antibody ICP-B161 Targeting TL1A and IL-23p19 in China
InnoCare Pharma a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases announced today that the Center for Drug Evaluation CDE of Chinas National Medical Products Administration NMPA has approved its Investigational New Drug IND application for ICPB a bispeci...
Mint Pharmaceuticals and Bayer Expand Medicine Distribution in Canada
Mint Pharmaceuticals and Bayer have expanded their distribution partnership in Canada to include several additional medicines across womens health cardiovascular care and anticoagulation
